Skip to main content

Diabetes is Danger?

 Researchers are observing a new long-term health concern in patients hospitalized with COVID-19: an increase in new-onset high blood sugar, or hyperglycemia, lasting months after infection.

An Italian study published in Nature Medicine found that about half of the patients admitted to the hospital for COVID-19 during the start of the pandemic had new cases of hyperglycemia. They also had poorer outcomes from COVID-19.

“These people were not diabetic before,” said lead author Paolo Fiorina, Harvard Medical School lecturer on pediatrics, part-time, at Boston Children’s Hospital. “But during admission, about 46 percent of the patients were found to have new hyperglycemia.”

Most cases resolved. However, about 35 percent of the newly hyperglycemic patients still had high blood sugar at least six months after infection.

The study is one of the first to show that COVID-19 has a direct effect on the pancreas, said Fiorina. “It indicates that the pancreas is another target of the virus, affecting not only the acute phase during hospitalization but potentially also the long-term health of these patients.”

The study assessed the health of 551 people admitted to the hospital in Italy from March 2020 through May 2020. A follow-up period included observations through six months after hospital admission.

Compared with patients who had no signs of glucose abnormalities, the hyperglycemic patients had:

  • longer hospitalizations

  • worse clinical symptoms

  • a higher need of oxygen

  • a higher need of ventilation

  • more need of intensive care treatment

“We wanted to understand the mechanism why these patients did poorly compared to those who did not have hyperglycemia,” said Fiorina, who published an earlier paper showing that COVID-19 worsens blood sugar control in people with diabetes.

Out of balance

To learn more, the researchers fitted all patients with a glucose sensor at admission. Over time, they detected many abnormalities in glucose metabolic control in the hyperglycemic patients.

They also found that hyperglycemic patients had abnormal hormone levels.

“We discovered they were severely hyperinsulinemic; they produced too much insulin,” said Fiorina.

They also had abnormal levels of proinsulin, a precursor of insulin, and markers of impaired islet beta cell function. Islet beta cells make and secrete insulin.

“Basically, the hormonal profile suggests that the endocrine pancreatic function is abnormal in those patients with COVID-19 and it persists long after recovery,” he said.

Hyperglycemic patients also had severe abnormalities in the number of inflammatory cytokines, including IL-6 and others.

“We thought that blocking IL-6, and potentially even other cytokines, would be a benefit for beta cell function,” said Fiorina.

His theory was proven true. Patients treated with anti-IL-6 therapy, tocilizumab, had greater improvement in blood sugar control compared with those who did not receive the medication.

Oncoming wave?

While glucometabolic abnormalities declined over time in some patients—particularly after COVID-19 infection waned—other issues remained.

Many patients had higher blood sugar levels after eating and abnormal pancreatic hormones in the post-COVID-19 period.

The study points to the importance of evaluating pancreatic function in patients hospitalized for COVID-19, both while in the hospital and over the long term, said Fiorina.

“This goes beyond fasting glucose testing because we observed glucose metabolic abnormalities during the day which were not always present in a normal fasting test,” he said.

In terms of treatment, questions remain about how to care for patients with COVID-19-related glucose abnormalities. Should patients be treated with just an antidiabetic drug like an insulin sensitizer, or should anti-inflammatory drugs like tocilizumab and other drugs be used?

“If you keep targeting and blocking insulin, but you have a strong and chronic inflammation, it may lead to chronic damage,” said Fiorina.

He suggests larger studies need to be done to test antidiabetes and anti-inflammatory treatment.

“When you consider how many patients have been hospitalized with COVID-19, and continue to be worldwide, we may see a huge increase in the diabetic population.”

Comments

Post a Comment

Popular posts from this blog

Feeling of smell is our most quick admonition framework

  Feeling of smell is our most quick admonition framework The capacity to recognize and respond to the smell of a potential danger is a precondition of our and other vertebrates' endurance. Utilizing an original strategy, scientists at Karolinska Institutet have had the option to concentrate on what occurs in the cerebrum when the focal sensory system passes judgment on a smell to address risk.  The review, which is distributed in PNAS, demonstrates that negative scents related with repulsiveness or disquiet are handled sooner than positive scents and trigger an actual aversion reaction.  Delineation by Behzad Iravani/Karolinska Institutet  "The human aversion reaction to disagreeable scents related with risk has for some time been viewed as a cognizant intellectual interaction, yet our review shows interestingly that it's oblivious and incredibly quick," says the concentrate's first creator Behzad Iravani, analyst at the Division of Clinical Neuroscience, Karolin...
Post a Comment
Read more

First-in-Human Trial with CAR Macrophages Shows the Cell Therapy May Be Safe, Feasible for Solid Tumors

  First-in-Human Trial with CAR Macrophages Shows the Cell Therapy May Be Safe, Feasible for Solid Tumors Penn study exhibits that designed macrophages, which can be designated to growths, might be a potential new safe based therapy of certain tumors. Primer discoveries from Penn Medicine in a continuous first-in-human clinical preliminary looking at the security, decency and attainability of fanciful antigen receptor macrophage (CAR-M) has assisted with building up the reasonability of this inventive immunotherapy, which propels the exploring logical disclosure of CAR T cell treatment additionally spearheaded at Penn-for strong disease growths and offers a promising new technique in the battle against disease. Fundamental information from the Phase 1 multi-focus clinical preliminary, which utilizes a novel, quality based disease treatment with CAR-designed macrophages to target repetitive or metastatic HER2-positive strong growths, was introduced during the new Society for Immunot...
Post a Comment
Read more

Rocket Lab will dispatch its first Moon mission from New Zealand in late 2021

 First moon mission from New Zealand in 2021 Rocket Lab is narrowing down the details for its first Moon launch. The private spaceflight firm has revealed that its CAPSTONE mission will lift off from the company's original launch complex in New Zealand sometime in the fourth quarter of 2021. The mission was originally slated to launch in early 2021 from NASA's Wallops facility in Virginia. The CAPSTONE (Cislunar Autonomous Positioning System Technology Operations and Navigation Experiment) cubesat will serve as a vanguard for NASA's Artemis program. It will verify the propulsion needs for a highly elliptical lunar orbit, test spacecraft-to-spacecraft navigation systems and show the potential for private support in future missions. A successful mission would help NASA's future Gateway spacecraft safely approach and orbit the Moon. The launch should also represent a technical breakthrough for Rocket Lab. While the Electron rocket will serve a familiar role in carrying the...
Post a Comment
Read more